Alder BioPharma Confirms Data For Chronic Migraine Candidate ALD403

(RTTNews) - Alder BioPharmaceuticals, Inc. (ALDR) Monday announced positive data in a 24-week phase 2b trial with its monoclonal antibody product candidate ALD403 in chronic migraine patients.

ALD403 targets calcitonin gene-related peptide. Earlier in March, phase 2b study using 300 mg and 100 mg dose levels has achieved primary efficacy endpoint of 75 percent reduction in migraine days over 12 weeks, and the secondary efficacy endpoint of mean reduction in migraine days from baseline. The 24 week study confirmed its 12 week trial.

The company said the data will help finalizing the dose selection and design of its second planned pivotal trial PROMISE 2. The Phase 2b clinical trial is a double-blind, placebo-controlled, randomized, single intravenous infusion, dose-ranging study in patients with chronic migraine.

Migraine is a common neurological disorder that results in suffering caused by intense sharp or throbbing pain in the head, commonly accompanied by nausea, vomiting and high sensitivity to light and sound. The Migraine Research Foundation estimates U.S. employers lose more than $13 billion each year as a result of 113 million lost work days due to migraine.